IMMUNOMEDICS, INC.

Company Information

Company Name
IMMUNOMEDICS, INC.
Address
300 The American Road
Morris Plains, NJ, 07950-
Phone
n/a
URL
n/a
DUNS
115350605
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$4,518,741.00
36
SBIR Phase II
$10,185,987.00
10
STTR Phase I
$191,143.00
1

Award List

  1. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

    Amount: $2,828,873.00

    DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for i ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. MONOCLONAL ANTIBODY FOR THERAPY AND DIAGNOSIS

    Amount: $500,000.00

    THE CONTINUING DEVELOPMENT AND EVALUATION OF NEW RADIOCHELATION AGENTS ARE OF UTMOST IMPORTANCE IN TUMOR IMAGING WITH ANTICANCER ANTIBODIES. WHILE DTPA-LABELED IN-111-RADIOIM-MUNOPHARMACEUTICALS ARE W ...

    SBIR Phase II 1988 Department of Health and Human Services
  3. THE OBJECT OF THIS PROJECT IS TO PRODUCE A KIT THAT UTILIZES ANTI-CSAP MONOCLONAL ANTIBODIES (MABS) FOR CLINICAL RADIOIMMUNODETECTION (RAID) OF COLORECTAL AND PANCREATIC CANCERS.

    Amount: $50,000.00

    THE OBJECT OF THIS PROJECT IS TO PRODUCE A KIT THAT UTILIZES ANTI-CSAP MONOCLONAL ANTIBODIES (MABS) FOR CLINICAL RADIOIMMUNODETECTION (RAID) OF COLORECTAL AND PANCREATIC CANCERS. PHASE I WILL BE DEVOT ...

    SBIR Phase I 1985 Department of Health and Human Services
  4. THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT.

    Amount: $50,000.00

    THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT. ANTIBODIES WILL BE COUPLED THROUGH ONE COVALENT BOND TO A SMALL POLYLYSINE UNIT. THE LATTER WILL CARRY ...

    SBIR Phase I 1985 Department of Health and Human Services
  5. THIS PROJECT IS CONCERNED WITH THE DEVELOPMENT OF NONENZYMATIC REAGENTS FOR IMMUNOHISTOCHEMISTRY, WITH EMPHASIS ON ADAPTING THE NEW TECHNOLOGY TO THE EXPANDING FIELD OF IMMUNOHISTOCHEMICAL DIAGNOSIS OF CANCER.

    Amount: $50,000.00

    THIS PROJECT IS CONCERNED WITH THE DEVELOPMENT OF NONENZYMATIC REAGENTS FOR IMMUNOHISTOCHEMISTRY, WITH EMPHASIS ON ADAPTING THE NEW TECHNOLOGY TO THE EXPANDING FIELD OF IMMUNOHISTOCHEMICAL DIAGNOSIS O ...

    SBIR Phase I 1985 Department of Health and Human Services
  6. THE AIM OF THIS PHASE I PROJECT IS TO DEVELOP NOVEL ANTIBODYCONJUGATES FOR USE IN THE RADIOIMMUNODETECTION OF TUMORS.

    Amount: $50,000.00

    THE AIM OF THIS PHASE I PROJECT IS TO DEVELOP NOVEL ANTIBODYCONJUGATES FOR USE IN THE RADIOIMMUNODETECTION OF TUMORS. IN RESPONSE TO THE PROBLEMS ASSOCIATED WITH THE ANTIBODY- DTPA-RADIOMETAL IMAGING ...

    SBIR Phase I 1986 Department of Health and Human Services
  7. THE PRODUCTION OF 188 RE-LABELED MONOCLONAL ANTIBODIES

    Amount: $50,000.00

    THE AIM OF THIS PROJECT IS TO ULTIMATELY DEVELOP NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER. THE AGENTS ARE BASED ON THE USE OF RADIOLABELED MONOCLONAL ANTIBODY BEARING THE ISOTOPE, RHENIUM- ...

    SBIR Phase I 1992 Department of Health and Human Services
  8. Carcinoembryonal Antigen Idiotype Vaccine

    Amount: $50,000.00

    Cancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising pr ...

    SBIR Phase I 1993 Department of Health and Human Services
  9. Humanized Antibody (MA5) for Breast Cancer Treatment

    Amount: $49,999.00

    The objective is to re-engineer a murine monoclonal antibody (MAb) by recombinant DNA technologies in order to more effectively treat breast carcinoma patients by the in vivo administration of radioim ...

    SBIR Phase I 1993 Department of Health and Human Services
  10. Engineering a Unique Conjugation Site on AB Light Chain

    Amount: $75,000.00

    Our objective is to establish that the naturally occurring asparagine- (Asn)- glycosylation sitefound in the light chain variable domain (VK) of a monoclonal antibody (MAb); LL2, is a potential site f ...

    SBIR Phase I 1994 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government